Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

Katerina Chatzidionysiou; Elisabeth Lie; Evgeny Nasonov; Galina Lukina; Merete Lund Hetland; Ulrik Tarp; Cem Gabay; Piet L C M van Riel; Dan C Nordström; Juan Gomez-Reino; Karel Pavelka; Matija Tomsic; Tore K Kvien; Ronald F van Vollenhoven

doi:10.1136/ard.2010.148759

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

Katerina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, Galina Lukina, Merete Lund Hetland, Ulrik Tarp, Cem Gabay, Piet L C M van Riel, Dan C Nordström, Juan Gomez-Reino, Karel Pavelka, Matija Tomsic, Tore K Kvien, Ronald F van Vollenhoven

215 Citations (Scopus)

Abstract

To assess the 6-month effectiveness of the first rituximab (RTX) course in rheumatoid arthritis (RA) and to identify possible predictors of response.

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	70
Issue number	9
Pages (from-to)	1575-1580
Number of pages	6
ISSN	0003-4967
DOIs	https://doi.org/10.1136/ard.2010.148759
Publication status	Published - 2011

Keywords

Adult
Aged
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents
Arthritis, Rheumatoid
Autoantibodies
Biological Markers
Drug Evaluation
Epidemiologic Methods
Female
Humans
Male
Middle Aged
Peptides, Cyclic
Prognosis
Rheumatoid Factor
Treatment Failure
Treatment Outcome
Tumor Necrosis Factor-alpha

Access to Document

10.1136/ard.2010.148759

Fingerprint

Dive into the research topics of 'Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries'. Together they form a unique fingerprint.

Cite this

Chatzidionysiou, K., Lie, E., Nasonov, E., Lukina, G., Hetland, M. L., Tarp, U., Gabay, C., van Riel, P. L. C. M., Nordström, D. C., Gomez-Reino, J., Pavelka, K., Tomsic, M., Kvien, T. K., & van Vollenhoven, R. F. (2011). Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Annals of the Rheumatic Diseases, 70(9), 1575-1580. https://doi.org/10.1136/ard.2010.148759

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. / Chatzidionysiou, Katerina; Lie, Elisabeth; Nasonov, Evgeny et al.
In: Annals of the Rheumatic Diseases, Vol. 70, No. 9, 2011, p. 1575-1580.

Research output: Contribution to journal › Journal article › Research › peer-review

Chatzidionysiou, K, Lie, E, Nasonov, E, Lukina, G, Hetland, ML, Tarp, U, Gabay, C, van Riel, PLCM, Nordström, DC, Gomez-Reino, J, Pavelka, K, Tomsic, M, Kvien, TK & van Vollenhoven, RF 2011, 'Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries', Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1575-1580. https://doi.org/10.1136/ard.2010.148759

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Annals of the Rheumatic Diseases. 2011;70(9):1575-1580. doi: 10.1136/ard.2010.148759

@article{4d93fea41dca40fbb8632d05c6e66e6c,

title = "Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries",

abstract = "To assess the 6-month effectiveness of the first rituximab (RTX) course in rheumatoid arthritis (RA) and to identify possible predictors of response.",

keywords = "Adult, Aged, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents, Arthritis, Rheumatoid, Autoantibodies, Biological Markers, Drug Evaluation, Epidemiologic Methods, Female, Humans, Male, Middle Aged, Peptides, Cyclic, Prognosis, Rheumatoid Factor, Treatment Failure, Treatment Outcome, Tumor Necrosis Factor-alpha",

author = "Katerina Chatzidionysiou and Elisabeth Lie and Evgeny Nasonov and Galina Lukina and Hetland, \{Merete Lund\} and Ulrik Tarp and Cem Gabay and \{van Riel\}, \{Piet L C M\} and Nordstr{\"o}m, \{Dan C\} and Juan Gomez-Reino and Karel Pavelka and Matija Tomsic and Kvien, \{Tore K\} and \{van Vollenhoven\}, \{Ronald F\}",

year = "2011",

doi = "10.1136/ard.2010.148759",

language = "English",

volume = "70",

pages = "1575--1580",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "9",

}

TY - JOUR

T1 - Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

AU - Chatzidionysiou, Katerina

AU - Lie, Elisabeth

AU - Nasonov, Evgeny

AU - Lukina, Galina

AU - Hetland, Merete Lund

AU - Tarp, Ulrik

AU - Gabay, Cem

AU - van Riel, Piet L C M

AU - Nordström, Dan C

AU - Gomez-Reino, Juan

AU - Pavelka, Karel

AU - Tomsic, Matija

AU - Kvien, Tore K

AU - van Vollenhoven, Ronald F

PY - 2011

Y1 - 2011

N2 - To assess the 6-month effectiveness of the first rituximab (RTX) course in rheumatoid arthritis (RA) and to identify possible predictors of response.

AB - To assess the 6-month effectiveness of the first rituximab (RTX) course in rheumatoid arthritis (RA) and to identify possible predictors of response.

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antirheumatic Agents

KW - Arthritis, Rheumatoid

KW - Autoantibodies

KW - Biological Markers

KW - Drug Evaluation

KW - Epidemiologic Methods

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Peptides, Cyclic

KW - Prognosis

KW - Rheumatoid Factor

KW - Treatment Failure

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

UR - https://www.scopus.com/pages/publications/80051473134

U2 - 10.1136/ard.2010.148759

DO - 10.1136/ard.2010.148759

M3 - Journal article

C2 - 21571731

SN - 0003-4967

VL - 70

SP - 1575

EP - 1580

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 9

ER -

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this